Claim OwnershipLife Science Today
Subscribed: 8Played: 204
Subscribe
© 2022 Life Science Today
Description
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
113 Episodes
Reverse
This week, I have an announcement to make. Find out more athttps://LifeScienceTodayPodcast.comAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Vaccine hesitancy, the most expensive gene therapy in the world, a $178M series D, and a $1.3B buyoutFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesSanofi/TakedaUniQure & CSLFog PharmaMerck + Imago About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
A $145M opioid acquisition, biobucks for the holidays, a series A, and diabetes approvalsFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesIndivior + OpiantRegeneron + CytomXRezoProventionAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
More CRISPR data, oncology wins, and a new player in ophthalmologyFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesIntelliaRegeneronViatris + Oyster PointAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Billion-dollar acquisitions, troubled waters for some biotech’s, and a prosperous outlook for othersFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesSumitovant + MyovantThermo Fisher + Binding Site GroupAstellas & TayshaAgiosVaxctyeAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Some statistically significant guidance, seed to acquisition, some biobucks, and the CART of the future. Find out more athttps://LifeScienceTodayPodcast.comStory References FDAAbbVie + DJSRoche + HookipaKyvernaAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
One biotech is on a roll, another is moving quickly, Amazon money for cancer, and some clinical development news Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesDICEOdysseyFred HutchMerck (MSD), Merck Story 2About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Major Alzheimer’s news, an ALS approval, and expanded therapies for skin conditionsFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesEisai + BiogenAmylyxSanofi + RegeneronAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
A $900 raise, gene therapy news, a quick IPO, and merge three for $100MFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesAlnylam, Link 2, Link 3Intellia TherapeuticsThird Harmonic BioGalvanize TherapeuticsAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
A critical aesthetics approval, site network buy-up, a very normal oncology biotech, and a busy week for one company. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesRevanceVelocity + MedPharmicsArsenalSpringWorks Link 1, Link 2, Link 3About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
A $1.1B acquisition, two FDA approvals, and grants for mRNA vaccines. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesNovo + FormaSanofiBoehringer IngelheimArcturusAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Ophthalmology acquisitions, following the pharma trends, and a move in healthcare that is not technology related. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesAlcon + AerieNovartis + SandozLabcorp + RWJBHAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Gene therapy approval, opioid costs continue, a $650M deal, and a $3.5B RNA partnership. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesBluebirdEndo & PharmaciesGenentech + JemincareMerck + OrnaAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Spending that COVID money, brain money, Irish money, and another oncology approval. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesPfizerCerevelAbbottAstraZeneca + Daiichi SankyoAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
This week, we take a break from stories of raising capital, mergers, and FDA approvals to look at the dark side of our industry. What happens when companies fail, people lie, and good drugs make bad lives? Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesZymergen + GinkgoCassavaTeva About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
There’s a SPAC, expanded FDA approval, more of the common, and two Bs, two AsFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesZyVersaIncyteRevolutionFronteraCAMP4ForSightAuronAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Cell therapy acquisition, royalties sold, biobucks-like deal, successful raise, and Chinese Venture Capital Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesVertex + ViaCyteTheravance BiopharmaMerck + OrionPliant Therapeutics QimingAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
FEED DROP - Clinical Research Evolved Noah and John talk with Dan Agroskin, a managing director at a leading private equity firm with a focus on the clinical research industry. We discuss how investments shape industries, what entrepreneurs should think about private equity, and the forces that drive exceptional business growth.Find Out MoreDan AgroskinClinical Research EvolvedNoah Goodson, PhDJohn ReitesKyle RickettsAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Double acquisition, private money, affordable deals, and a surprising $70M launchFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesGalapagos + CellPoint + AboundBioRadiusIpsen + EpizymeDEM Bio About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Crohn’s approval, new VC round, direct offerings, and potential asset sales. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesAbbVieThird RockScholar RockKyowa Kirin About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Comments
Download from Google Play
Download from App Store
United States